How much did Q32 Bio raise?

Q32 Bio raised $60 Million in a Series B round on October 29, 2020.

Where is Q32 Bio based and how big is it?

Q32 Bio is based in Waltham, Massachusetts, United States. Fundz records about 34 employees.

Who are the decision-makers at Q32 Bio?

Fundz holds 1 contact at Q32 Bio, including the Founder and Principal Consultant. Names and contact details are shown to Fundz members.

Q32 Bio Closes $60 Million Series B Financing, Advances to Clinical Stage Research in Therapeutics Designed to Restore Immune Homeostasis

PUBLIC · QTTBOct 29, 2020

Amount Raised

$60 Million

Round Type

Series B

WalthamBiotechnologyHealthcareHealth CareTherapeutics

Description

Q32 Bio, a biotechnology company developing biologic therapeutics to restore healthy immune regulation, today announced the completion of a $60 million Series B financing co-led by OrbiMed Advisors and Acorn Bioventures. The company also announced the commencement of a Phase 1 clinical trial evaluating its best-in-class IL-7R antibody ADX-914, a significant milestone marking Q32 Bio's entry into clinical-stage development.

Quick answer

Q32 Bio raised $60 Million in a Series B round, dated October 29, 2020. Q32 Bio is based in Waltham, Massachusetts, United States.

How much did Q32 Bio raise?: Q32 Bio raised $60 Million in a Series B round on October 29, 2020.
What does Q32 Bio do?: Q32 Bio is a clinical stage biotechnology company whose science targets potent regulators of the adaptive immune system to re-balance immunity and is focused on developing innovative therapies for alopecia areata and..
Where is Q32 Bio based and how big is it?: Q32 Bio is based in Waltham, Massachusetts, United States. Fundz records about 34 employees.
Who are the decision-makers at Q32 Bio?: Fundz holds 1 contact at Q32 Bio, including the Founder and Principal Consultant. Names and contact details are shown to Fundz members.

Source: Fundz verified event record.

Who else raised in Healthcare and Therapeutics around the same time

Companies in the same sectors as Q32 Bio that raised within 45 days of this round, from Fundz verified event records.

Azora Therapeutics, Inc. (DE) raised $296K on November 30, 2020.
Imago BioSciences, Inc. raised $80M on November 20, 2020.
Longboard Pharmaceuticals raised $56M on November 18, 2020.
Elevation Oncology raised $65M on November 18, 2020.
Definium Therapeutics raised $248K (Seed) on November 13, 2020.
Damora Therapeutics, Inc. raised $64M on November 5, 2020.

Who to call at Q32 Bio, and when

A new round usually means Q32 Bio is about to hire and buy. The teams that reach out first get the meeting.

An alert the day Q32 Bio raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at Q32 Bio, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Q32 Bio. With Fundz connected, it knows.

Watch Fundz in

See plan options

Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Q32 Bio

Location

Waltham, Massachusetts, United States

About

Q32 Bio is a clinical stage biotechnology company whose science targets potent regulators of the adaptive immune system to re-balance immunity and is focused on developing innovative therapies for alopecia areata and other autoimmune and inflammatory diseases. Per the National Alopecia Areata Foundation, about 700,000 people in the United States live with alopecia areata, a disease which has a life-altering impact on patients and limited current treatment options. The Company is advancing bempikibart (ADX-914), a fully human anti-IL-7Rα antibody that re-regulates adaptive immune function, for the treatment of alopecia areata in an ongoing Phase 2 program. The IL-7 and TSLP pathways have been genetically and biologically implicated in driving several T cell-mediated pathological processes in numerous autoimmune diseases.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Q32 Bio raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Book a demo Explore plans

Related People

1 contact

Verified contactsJoel S., Founder and Principal Consultant hiddenSee plans and pricing

Predictive Intelligence

Strategic

ML-powered predictions for Q32 Bio's next move

See what Strategic adds

Funding Insights

What this usually means

Timeline to next round

Series B companies typically work for 15-20 months before raising new capital

Growth expectations

Series B companies are expected to scale rapidly and expand market reach

Q32 Bio raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

Show me how a sales rep uses this Or see plans and pricing →

5 screens from a live account. No signup.